Zymeworks (ZYME) announced that its board of directors has authorized a share repurchase program under which the company may repurchase up to $125M of its outstanding common stock. “The authorization of this 2026 share repurchase program reflects our continued focus on disciplined capital allocation and long-term value creation,” said Kenneth Galbraith, chair and CEO of Zymeworks. “We believe this program provides an efficient mechanism to return capital to stockholders, while preserving the flexibility to further invest in our R&D pipeline and pursue strategic opportunities”.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZYME:
- Zymeworks Authorizes 2026 Share Repurchase Program, Affirms Liquidity
- Zymeworks Maintained at Buy as Analyst Highlights Cash Runway, Upcoming Catalysts and Reiterates $46 Price Target
- Zymeworks’ Earnings Call Balances Progress And Pressure
- Zymeworks: Strong Ziihera Royalty Momentum and Deep Oncology Pipeline Underpin Buy Rating and Favorable Risk-Reward
- Zymeworks reports Q1 EPS (59c), consensus (10c)